Abstract
A series of novel sulfonylamino pyrrolidine derivatives were synthesized, characterized and evaluated for their antimicrobial activity. All compounds exhibited moderate activity against the microorganisms tested. The compounds were evaluated in silico for their ability to inhibit epidermal growth factor receptor (EGFR). Docking in silico demonstrated that the sulfonylamino pyrrolidine derivatives represent a new class of EGFR inhibitors and bind at the ATP binding pocket of the tyrosine kinase domain of EGFR. The free energy of binding and inhibition constant (k i) of the docked compounds were evaluated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
